Vaidotas Urbanavicius Sole Proprietor Enterprise
- Address
- lock Available on a paid plan
Vaidotas Urbanavicius Sole Proprietor Enterprise
Vaidotas Urbanavicius Sole Proprietor Enterprise is a clinical research facility specializing in endocrine disorders and hormonal therapies. The center focuses on evaluating novel therapeutic approaches for patients with complex pituitary disorders who require advanced treatment options beyond conventional first-line therapies.
- Acromegaly treatment and management in patients with inadequate response to standard somatostatin analog therapy
- Investigation of innovative growth hormone regulatory agents and their efficacy in maintaining normal IGF-1 levels
- Double-blind, placebo-controlled trials assessing long-term safety and maintenance therapy in endocrine conditions
The research center has particular expertise in conducting randomized controlled trials for rare endocrine diseases, with a focus on acromegaly patients who have previously been treated with somatostatin analogs. Their clinical trial capabilities include precise monitoring of biochemical markers such as Insulin-like growth factor 1 (IGF-1) levels and assessment of therapeutic maintenance over extended periods.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Debiopharm International S.A.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 79 other sites in Lithuania
Therapeutic Area Benchmark — Lithuania
Select a therapeutic area to compare against other sites in Lithuania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Lithuania
Market Share
Country: Lithuania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vaidotas Urbanavicius Sole Proprietor Enterprise
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Debio 4126, a 12-Week Octreotide Formulation, in Acromegaly Patients Previously Treated with Somatostatin Analogs | Debiopharm International S.A. | Phase III | Recruiting | Jul 2025 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lanreotide | 1 | Unknown | 2025-07-23 | 2025-07-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.